>

PROTALIX Stock Today

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:4em;padding-top: 25px;;'>PR</div>
PROTALIX BIOTHERAP is trading at 783.00 as of the 5th of April 2020, which is 3.9 percent decrease since the beginning of the trading day. The stock's open price was 814.8. PROTALIX BIOTHERAP has 51 percent ods of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 30 days. Equity ratings for PROTALIX BIOTHERAP are calculated based on the Macroaxis scoring framework. The performance scores are derived for the period starting the 6th of January 2020 and ending today, the 5th of April 2020. Click here to learn more.
Analyze Filter   Check how we calculate scores

  Performance0 100 

PROTALIX BIOTHERAP Profile

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. Protalix BioTherapeutics, Inc. was founded in 1993 and is headquartered in Karmiel, Israel. PROTALIX BIOTHERAP operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 196 people. more on PROTALIX BIOTHERAP
Legal NamePROTALIX BIOTHERAP
Chairman of the BoardShlomo YanaiView All
Thematic Classifications
Active investing themes PROTALIX BIOTHERAP currently participates. An investing theme is an unweighted collection of funds, stocks, ETFs or cryptocurrencies
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance.
Horizon: 30 days (very short)Advice
PROTALIX BIOTHERAP (PLX) is traded on Tel Aviv Stock Exchange in Israel and employs 196 people. The company currently falls under 'Small-Cap' category with current market capitalization of 120.31 M. PROTALIX BIOTHERAP operates under Healthcare sector and is part of Biotechnology industry. The entity has 14.84 M outstanding shares. PROTALIX BIOTCS has accumulated about 17.79 M in cash with (19.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.2.
Check PROTALIX BIOTHERAP Probability Of Bankruptcy

Ownership Allocation (%)

PROTALIX Stock Price Odds Analysis

Odds Down 783.0HorizonTargetOdds Up 783.0
59.89%30 days
 783.00 
40.05%
Based on normal probability distribution, the odds of PROTALIX BIOTHERAP to move above current price in 30 days from now is about 40.05 (This PROTALIX BIOTHERAP probability density function shows the probability of PROTALIX BIOTHERAP Stock to fall within a particular range of prices over 30 days) .

PROTALIX BIOTHERAP Risk Profiles

PROTALIX Stock Against Markets

Did you try this?

Run Portfolio Backtesting Now

   

Portfolio Backtesting

Avoid under-diversification and over-optimization by backtesting your portfolios
All  Next Launch Module
Please check Your Equity Center. Please also try Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page